Protagonist Therapeutics Stock Forecast, Price & News

-0.49 (-1.13 %)
(As of 06/24/2021 02:51 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume11,789 shs
Average Volume386,169 shs
Market Capitalization$1.88 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Protagonist Therapeutics logo

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.74 out of 5 stars

Medical Sector

1292nd out of 2,105 stocks

Pharmaceutical Preparations Industry

584th out of 832 stocks

Analyst Opinion: 1.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

Is Protagonist Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Protagonist Therapeutics stock.
View analyst ratings for Protagonist Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Protagonist Therapeutics?

Wall Street analysts have given Protagonist Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protagonist Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 3,900,000 shares, an increase of 26.2% from the April 29th total of 3,090,000 shares. Based on an average trading volume of 320,600 shares, the short-interest ratio is currently 12.2 days.
View Protagonist Therapeutics' Short Interest

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Protagonist Therapeutics

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its earnings results on Tuesday, May, 4th. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.03. The business had revenue of $6.19 million for the quarter, compared to analysts' expectations of $3.75 million. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 31.99% and a negative net margin of 224.79%.
View Protagonist Therapeutics' earnings history

How has Protagonist Therapeutics' stock price been impacted by COVID-19?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 497.5% and is now trading at $42.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PTGX?

7 Wall Street analysts have issued 12-month target prices for Protagonist Therapeutics' stock. Their forecasts range from $27.00 to $53.00. On average, they expect Protagonist Therapeutics' stock price to reach $43.38 in the next year. This suggests a possible upside of 1.4% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim PAO, Sec. & Director (Age 64, Pay $1.04M)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. (Age 71, Pay $719.42k)
  • Dr. Suneel K. Gupta, Chief Devel. Officer (Age 63, Pay $680.32k)
  • Dr. Richard S. Shames, Clinical Advisor (Age 61)
  • Mr. Donald A. Kalkofen, Chief Financial Officer (Age 57)
  • Mr. Mohammad Masjedizadeh, Exec. VP & CTO
  • Mr. Matthew M. Gosling, Exec. VP & Gen. Counsel (Age 50)
  • Ms. Carena Spivey, Exec. Director of HR
  • Dr. Ashok Bhandari, Sr. VP of Discovery Chemistry & Process Research (Age 57)
  • Dr. Larry Mattheakis, Sr. VP of Discovery Biology & Translational Research (Age 64)

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (9.01%), RTW Investments LP (7.98%), BlackRock Inc. (6.83%), Deerfield Management Company L.P. Series C (2.86%), Point72 Asset Management L.P. (2.14%) and Price T Rowe Associates Inc. MD (2.08%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Sarah B Noonberg and Suneel Gupta.
View institutional ownership trends for Protagonist Therapeutics

Which institutional investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, RTW Investments LP, Goldman Sachs Group Inc., D. E. Shaw & Co. Inc., Deerfield Management Company L.P. Series C, JPMorgan Chase & Co., Atom Investors LP, and Bank of Montreal Can. Company insiders that have sold Protagonist Therapeutics company stock in the last year include Dinesh V Ph D Patel, and Sarah B Noonberg.
View insider buying and selling activity for Protagonist Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was purchased by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., BlackRock Inc., Point72 Asset Management L.P., Obermeyer Wood Investment Counsel Lllp, Sphera Funds Management LTD., Geode Capital Management LLC, Sei Investments Co., and Citigroup Inc.. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta.
View insider buying and selling activity for Protagonist Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $42.78.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics has a market capitalization of $1.88 billion and generates $28.63 million in revenue each year. The company earns $-66,150,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

Protagonist Therapeutics employs 83 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is

Where are Protagonist Therapeutics' headquarters?

Protagonist Therapeutics is headquartered at 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.